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Application of Targeted 
Mass Spectrometry for the 
Quantification of Sirtuins in the 
Central Nervous System
T. Jayasena1, A. Poljak1,2,3, N. Braidy1, L. Zhong2, B. Rowlands3, J. Muenchhoff1, R. Grant3,4, 
G. Smythe3, C. Teo5, M. Raftery2 & P. Sachdev1,6
Sirtuin proteins have a variety of intracellular targets, thereby regulating multiple biological pathways 
including neurodegeneration. However, relatively little is currently known about the role or expression 
of the 7 mammalian sirtuins in the central nervous system. Western blotting, PCR and ELISA are 
the main techniques currently used to measure sirtuin levels. To achieve sufficient sensitivity and 
selectivity in a multiplex-format, a targeted mass spectrometric assay was developed and validated 
for the quantification of all seven mammalian sirtuins (SIRT1-7). Quantification of all peptides was by 
multiple reaction monitoring (MRM) using three mass transitions per protein-specific peptide, two 
specific peptides for each sirtuin and a stable isotope labelled internal standard. The assay was applied 
to a variety of samples including cultured brain cells, mammalian brain tissue, CSF and plasma. All 
sirtuin peptides were detected in the human brain, with SIRT2 being the most abundant. Sirtuins were 
also detected in human CSF and plasma, and guinea pig and mouse tissues. In conclusion, we have 
successfully applied MRM mass spectrometry for the detection and quantification of sirtuin proteins in 
the central nervous system, paving the way for more quantitative and functional studies.
Sirtuins are a class of proteins that possess histone deacetylase or mono-ribosyltransferase activity and play crit-
ical roles in cell survival in response to oxidative stress and caloric restriction (CR) regimes1. In mammals, seven 
sirtuins (SIRT1-7) have been identified. All mammalian sirtuins contain a conserved NAD-binding and catalytic 
domain, but differ in their N and C-terminal domains. They have different specific substrates including histones, 
transcriptional regulators and enzymes. They localise to cell compartments which regulate cellular structure, 
metabolism and gene expression, including the cytoskeleton (SIRT2), mitochondria (SIRT3, SIRT4 and SIRT5) 
and nucleus/nucleolus (SIRT1, SIRT6 and SIRT7), and play important roles in health and disease1. SIRT1 is the 
best characterized and has the broadest substrate specificity. Sirtuins have emerged as critical modulators of met-
abolic adaptive responses, and their activities have been linked to ageing and multiple diseases, from metabolic 
abnormalities to neurodegeneration.
Sirtuins can affect reactive oxygen species (ROS) production and promote resistance to their damaging effects. 
Oxidative stress has been shown to decrease SIRT1 expression in the hippocampus and cortex, possibly by direct 
degradation by ROS2. SIRT1 overexpression prevents oxidative stress-induced apoptosis and increases resistance 
to oxidative stress through regulation of the FOXO family of forkhead transcription factors3. The cytoplasmic 
sirtuin protein SIRT2, has been shown to increase in response to oxidative stress but promotes cell death through 
FOXO proteins4. SIRT3, a mitochondrial protein, reduces oxidative stress through activation of superoxidase dis-
mutase5. SIRT6 and SIRT7, like the founding member of the sirtuin family SIRT1, are nuclear proteins involved 
in oxidative-stress induced DNA repair through activation of the PARP-1 DNA repair enzyme.
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SIRT1 is expressed in the adult brain, in the cortex, hippocampus, cerebellum, and hypothalamus, and in 
lower levels in the white matter6. Among the brain cell types, SIRT1 is predominantly expressed in neurons 
and viewed as a nuclear protein6. The mRNAs for all seven sirtuins have been identified in mouse brain tissue 
and also neural stem cells7. SIRT1, SIRT2 and SIRT3 have also been detected in human serum, and levels were 
shown to decline with age and were linked to frailty8,9. SIRT3 is elevated at both the mRNA and protein levels in 
Alzheimer’s disease (AD) post mortem brain tissue compared to controls10.
The most common techniques currently utilised for detecting a change in sirtuin levels at the mRNA or pro-
tein level are PCR and western blotting, respectively (see Table 1). Other studies have used methods such as 
immunohistochemistry, surface plasmon resonance and ELISA assays (see Table 1). The majority of these meth-
ods are only semi-quantitative with moderate sensitivity, use antibodies which may not have sufficient specificity 
or detect expression at the mRNA level which may not reflect protein expression. Furthermore, there is no current 
assay which detects multiple sirtuins simultaneously.
Quantitative expression analysis of mammalian sirtuin proteins (especially SIRT2-7), across cell and tissue 
types is limited in the current literature. Previous studies have shown an increase in SIRT3 in AD post-mortem 
brain tissue using western blotting for protein expression and multiplex qPCR to assay SIRT3 mRNA levels10. 
Both SIRT3 protein and mRNA were shown to be significantly elevated in the AD group10. Another recent paper 
detected SIRT1 in human serum samples using western blotting, surface plasmon resonance and ELISA to meas-
ure SIRT1 protein levels8. SIRT1 declines with age and is more dramatically reduced in MCI and AD patients 
compared to age matched controls, suggesting that SIRT1 may warrant further investigation as a potential plasma 
biomarker for AD8. SIRT1 and SIRT3 levels in serum were found to be significantly lower in frail subjects as com-
pared to the non-frail9. Another study reported a decrease in SIRT1 and SIRT2 mRNA levels using quantitative 
real time PCR in the primary motor cortex of human post-mortem amyotrophic lateral sclerosis brain tissue11.
Mass spectrometry has been used to successfully assay metabolites of SIRT1 activator drugs in plasma and 
urine12, but to date has not been used to quantify protein levels directly. Mass spectrometry has a great advantage 
over the conventionally used antibody based methods, such as western blotting, in that it offers greater specificity, 
linearity, reproducibility and typical limits of quantification down to the low fmol range. It also removes some of 
the antibody specificity issues that are associated with methods such as western blotting and ELISA, as peptides 
unique to each protein are measured. Targeted MRM based mass spectrometry may provide a more specific and 
sensitive method to detect and quantify sirtuin expression at the protein level, providing a tool for comprehensive 
sirtuin protein expression analysis. The aim of this study was to develop a targeted mass spectrometry method 
using multiple reaction monitoring (MRM) to quantify the seven human sirtuins at the protein level and to apply 
the assay to CNS biological samples.
Results
Peptide standards. Standard curves for sirtuin peptides are shown in Fig. 1. The LOD and LOQ were deter-
mined when the signal to noise ratio of the transition with the highest intensity was approximately 3:1 and 10:1 
respectively. All peptides had good linearity in the 1–200 fmol/μ l range and intra- and inter- assay variance was 
< 10% and less than < 14% respectively. Representative chromatograms for each of the 14 peptides are shown in 
Supplementary Figure S1.
Sirtuin peptide standard curves spiked with buffer only (0.1% formic acid and no gel bit), blank gel bits and gel 
bits containing Hu6 depleted plasma had very similar regression equations and slopes, indicating modest matrix 
effects (Supplementary Figure S2). Sirtuin recoveries (from the gel spike experiment, Supplementary Figure S8), 
relative to sirtuin run in buffer only achieved 61–96% recovery and 58–131% recovery for the 5 μ g and 2 μ g sirtuin 
levels respectively (Supplementary Table S1).
Quantification of sirtuin expression in cells and tissues. In all the human primary brain cell types and 
human brain cell lines SIRT1, 2, 3, 6 and 7 were detected and quantified (Fig. 2). All seven sirtuins were detected 
Name Areas detected in CNS Function in CNS Techniques used
SIRT1
Human hippocampus and cortex6. Has also been detected 
in human serum at approx 8.16 ng/μ l8. Mouse neural 
stem cells and adult mouse brain7. Porcine brain21.
Modulates memory formation and synaptic plasticity. Reduces 
with age in mice. Metabolic sensor.
TR-qPCR6, immunohistochemistry41, western blotting, 
surface plasmon resonance and ELISA8.
SIRT2 Mouse neural stem cells and adult mouse brain
7.  
Porcine brain21. Human serum9.
Inhibitor of microglia-mediated inflammation and 
neurotoxicity18. Impairs neurite outgrowth and 
oligodendrocyte differentiation. Involved in myelin formation.
Mouse knockouts18, western blotting.
SIRT3
Cortex, Hippocampus and Cerebellum10. Mouse neural 
stem cells and adult mouse brain7. Porcine brain21.  
Rat brain. Human serum9.
Responses to oxidative stress and involved in maintenance of 
mitochondrial function. Western blotting and qPCR
10.
SIRT4 Mouse neural stem cells and adult mouse brain
7.  
Porcine brain21. Rat cortical cells and brain tissue42.
Regulation of glial development42; involved in glutamate 
transport and protective role against excitotoxicity43. qPCR, western blotting and immunofluorescence
21,42
SIRT5 Mouse neural stem cells and adult mouse brain
7.  
Porcine brain21.
SIRT5 gene polymorphism may promote molecular brain 




Mainly localised in the nucleus in the cortical layers45. 
Mouse neural stem cells and adult mouse brain7,46,47. Rat 
brain. Porcine brain21.
Regulator of somatic growth by modulating neural chromatin 
and gene activity46. Modulated DNA repair in the brain48. 
Suppresses proinflammatory gene expression.
Brain specific mouse knockout models and primary brain 
cell models46,48,49; immunohistochemistry45;  
western blotting, immunofluorescence47.
SIRT7 Mouse neural stem cells and adult mouse brain
7.  
Porcine brain21. Positive regulator of RNA polymerase I transcription. Mouse knockout
46.
Table 1.  Expression of sirtuins in the CNS and current methods used for analysis.
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in human control brain tissue, with SIRT2 highly expressed (Fig. 3, Panel A). Detergent fractionation into subcel-
lular groups improved identification of mitochondrial sirtuins (SIRT3–5) (Fig. 3, Panel B).
We were also able to quantify some sirtuins in guinea pig and mouse tissue due to their common sequences 
with human sirtuin peptides. SIRT1-3 levels in the guinea pig (Fig. 4, Panel A) and SIRT 1 and 3 levels in mouse 
organs (Fig. 4, Panel B) were quantified. Furthermore the method could be adapted for all sirtuins from other 
species with purchase of the appropriate synthetic peptides and their heavy internal standards. Supplementary 
Table S2 shows the level of homology (or identity) of human SIRT1-7 peptide sequences with mouse and guinea 
pig. All samples were fractionation on a 1D-SDS-PAGE to reduce sample complexity and improve detection sen-
sitivity. A workflow of the sample preparation procedure can be found in Supplementary Figure S3.
Another important issue is the existence of splice variants or isoforms of the sirtuin proteins. Supplementary 
Table S3 lists the sequences of all sirtuin isoforms and the location of the two MRM peptides within each 
sequence. The majority of sirtuin isoforms contain both peptides, and all contain at least one of the two peptide 
sequences used for quantification in this study.
Validation of MRM method with established protocols. Human brain cells and tissue samples were 
compared with established protocols for sirtuin detection such as immunohistochemical staining, PCR and west-
ern blotting. Immunohistochemical staining showed that all seven sirtuins are expressed in astrocytes (Fig. 5, 
panel A, rows 1–4) and control human frontal lobe brain tissue (Fig. 5, panel A, row 5). PCR identified SIRT1 
and SIRT2 mRNA in control human frontal, occipital and hippocampus brain tissue (Fig. 5, panel B). Western 
blotting confirmed the identification of SIRT1, 2 and 3 in control human frontal lobe brain tissue (Fig. 5, panel C 
and Supplementary Figure S4).
Quantification of sirtuins in CSF and immunodepleted plasma. SIRT1 was quantified in the CSF of 
five control patients and in control plasma immunodepleted of the six most abundant proteins. SIRT1 was the 
only sirtuin detected and was found to range from 4.30 ± 0.19 to 5.09 ± 0.53 fmol/μ g total protein in CSF and 
8.68 ± 0.35 fmol/μ g total protein in plasma. Individual data can be found in Supplementary Figure S5. SIRT2-7 
in CSF and immunodepleted plasma were found to be below the detection limits of the assay. All samples were 
fractionated by 1D-SDS-PAGE to reduce sample complexity and a workflow of the sample preparation procedure 
can be found in Supplementary Figure S3.
Discussion
The rapid expansion of instruments and software in the field of targeted protein quantification by MRM is 
expected to have vast applications in quantitative protein biochemistry13,14. Most of the currently used protocols 
to measure sirtuin changes in the CNS have ultilised methods such as ELISA, surface Plasmon resonance, western 
blotting and fluorescent staining. Mass spectrometry provides a platform that overcomes some of the limitations 
of antibody based approaches for protein quantification, in particular providing a level of specificity not avail-
able with the other approaches. Isotopically labelled peptide standards allow for quantification of protein levels 
and also provide the ability to monitor stability of analytes throughout the sample processing steps. This greatly 
simplifies the development of assays compared with standard immunological formats such as ELISA where 
well-characterised antibodies are needed. Furthermore MRM facilitates multiplexed analysis, identifying several 
proteins in a single run, thereby maximising information obtained per sample, minimising assay time while at 
the same time conserving precious samples. It measures several transitions per quantified protein, thus gener-
ating several independent measurements, and with the use of heavy peptide standards allows for generation of 
standard curves and accurate quantification. This approach has advantages over methods such as western blotting 
and staining techniques which are semi-quantitative at best and lack the level of structural specificity achieved by 
mass spectrometry. Our MRM approach is also complementary to PCR which targets mRNA levels only.
Perhaps the major limitation to mass spectrometry based protein quantification is throughput and cost. 
Immunological assays can be performed in 96 well plate formats and plate readers allow measurement of an 
entire plate in a single run. Mass spectrometry requires each sample to be run individually with longer run times. 
However one of the main advantages of mass spectrometry is its ability to specifically and accurately distinguish 
different isoforms or modified forms of proteins, even in complex samples. The sensitivity of mass spectrome-
try is very high but limitations to sensitivity of quantitative assays are often caused by the dynamic range of the 
proteins in the sample. Future developments in mass spectrometer analysers and detectors may help address this 
limitation. Even so, it is probable that improved sample purification/fractionation procedures will continue to be 
a vital element of the most challenging and complex proteomics problems, and to achieve the required sensitivity 
for robust quantification. For example in this study all samples were fractionation on a 1D-SDS-PAGE gel and gel 
bands excised and tryptic digested prior to MRM analysis to reduce sample complexity. A workflow of the sample 
preparation procedure can be found in Supplementary Figure S3.
MRM mass spectrometry was successfully utilised in this study to quantify seven mammalian sirtuins in 
human brain cells, tissues and fluid. Furthermore the method can be used to measure sirtuin expression in animal 
tissues, such as mouse and guinea pig, in cases where peptide sequences are identical to the human standards. 
In line with previous data, our results affirm that there is significant divergence in abundance amongst members 
of the sirtuin family of proteins in the brain. We report SIRT1 and SIRT2 to be the most abundant sirtuins in 
cultured brain cells with SIRT1 highest in neurons and SIRT2 highest in oligodendrocytes, validating previous 
studies showing SIRT2 to be highly expressed in oligodendrocytes15. Our study and others have also found SIRT2 
expressed in neurons and glial cells16,17. Further validation with higher sample numbers and across a wider range 
of cell lines may help elucidate differences between cell types for the lower abundant sirtuins.
We found SIRT2 to be the most abundant sirtuin in the adult human frontal lobe and cortex and cerebel-
lum homogenates from the guinea pig. SIRT2 is known to co-localise with microtubules and functions as a 
www.nature.com/scientificreports/
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tubulin-deacetylase. It is a suppressor of microglial activation and brain inflammation, with reduced levels of 
SIRT2 leading to increased production of free radicals and neurotoxicity, while its overexpression inhibits brain 
inflammation18. In other studies, however, it has been shown to increase in cells with oxidative stress and promote 
death cell4. In addition, SIRT2 inhibition has been shown to protect against Parkinson’s disease and Huntington’s 
Figure 1. Sirtuin peptide standard curves, variance and limits of detection and quantification. Sirtuin 
peptide standard curves (average of the peak area ratios for the two peptides, in triplicate for each sirtuin, with 
heavy peptide spike of 100 fmol/μ l). Both inter- and intra-assay variance were calculated for three replicates 
and the LOD and LOQ are shown in fmol/ul. CVs calculated using peptide peak area ratios (light/heavy) at the 
100 fmol/μ l peptide concentration level. Individual chromatograms for each of the 14 peptides can be found in 
Supplementary Figure S1.
www.nature.com/scientificreports/
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disease19,20. Previously published results have shown SIRT2 to be abundant in the brain and serum9,11,21,22 and our 
study provides further evidence for this and shows that it is also abundant in the guinea pig brain.
SIRT1 was the second-most abundant sirtuin in the brain and the only sirtuin detected in the CSF and plasma 
using our method. SIRT1 is a neuroprotective factor in a variety of models of neurodegenerative diseases, includ-
ing Huntington’s disease, Multiple Sclerosis and AD23,24. It increases following exposure to cellular stressors, 
including energy/nutrient depletion and has been linked to increased lifespan in animal models25. We were only 
Figure 2. Sirtuin expression in primary cultured brain cells and cell lines. In primary neurons SIRT1 was 
found to be the most abundant sirtuin (*p < 0.05) compared to other neuronal sirtuins (n = 3). SIRT2 was found 
to be abundant in primary oligodendrocytes (*p < 0.05) compared to other cell types (n = 3). SIRT1 and SIRT2 
were the most abundant in all the cell cultures. SIRT4 and SIRT5 were below the detection limits and only small 
amounts of SIRT6 and SIRT7 were detected.
Figure 3. Sirtuin expression in human frontal lobe brain tissue. Sirtuin expression in unfractionated 
(Panel A) and fractionated (Panel B) human frontal lobe brain tissue. All seven sirtuins were detected in 
unfractionated human frontal lobe brain tissue with SIRT2 the most abundant (*p < 0.05) compared to all other 
sirtuins (Panel A). The mitochondrial sirtuins (SIRT3-5) were found to be close to the LOQ, but their signals 
improved following fractionation of the tissue into cytosolic, nuclear, cytoskeletal and membrane fractions 
(Panel B). Fractionation showed SIRT1 and SIRT2 expressed in all fractions, whereas SIRT3-5 were below the 
LOD in the cytosol and SIRT6 and SIRT7 were below the LOD in the cytoskeletal fraction. SIRT1 was most 
abundant in the nucleus and SIRT2 in the cytoskeletal fraction (*p < 0.05, Panel B). In the cytosol, SIRT2 was 
the most abundant sirtuin (*p < 0.05), and all sirtuins were captured in the membrane fraction.
www.nature.com/scientificreports/
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able to detect SIRT1 in both CSF and plasma while Kumar et al. have recently identified SIRT1, SIRT2 and SIRT3 
in human serum using surface plasmon resonance9. The use of more sensitive mass spectrometry instrumen-
tation, and/or fractionation or enrichment of plasma proteins, may improve sensitivity for the other sirtuins in 
plasma.
The mitochondrial sirtuins SIRT3-5 were found at lower levels in human brain but detection was improved 
after detergent fractionation. Further fractionation of samples or purification/enrichment of mitochondria may 
facilitate improved mitochondrial sirtuin quantification. Our data also show that SIRT6 and SIRT7 are the third 
and fourth most abundant members of the sirtuins family in the adult human frontal lobe. Both SIRT6 and SIRT7 
have been associated with the maintenance of DNA stability and promotion of DNA repair following exposure 
to cellular stressors26,27.
We also confirm that mammalian sirtuins are localised to several subcellular compartments. While SIRT1, 
SIRT6 and SIRT7 are predominantly found in nuclear fractions, they are also detected in cytosol, cytoskeleton 
and membrane fractions, albeit at much lower levels. Similarly, although SIRT2 is the only human sirtuin primar-
ily localised in the cytoplasm, it may also be found at lower levels in the nucleus and cellular membrane. Our data 
confirm that SIRT1 and SIRT2 may interact with both the nuclear and cytoplasmic subcellular compartments. 
Similarly, while the mitochondrial sirtuins (SIRT3-5) were previously reported to be exclusively localised to the 
mitochondria, other studies have reported the localisation of several variants in the nucleus as well as the cyto-
plasm, in line with our study28. SIRT5 has recently been found to have both desuccinylase and de-malonylase 
activities in both the mitochondria and cytosol29,30. The expression patterns of sirtuins in brain cells remains 
controversial and it is unclear whether certain sirtuins are specific to cell types. Our MRM study indicates that the 
majority of sirtuins (SIRT1, 2, 6 and 7) are present across all the main brain cell types.
For validation, analyses of the samples by immunohistochemical staining confirmed that all seven sirtuins are 
found in human primary astrocytes (Fig. 5, panel A row 1–5). PCR detected SIRT1 and SIRT2 mRNA in frontal, 
occipital and hippocampal brain tissue (Fig. 5, panel B). Western blotting identified protein levels in frontal lobe 
brain tissue with SIRT2 showing the strongest bands (Fig. 5, panel C and supplementary Figure S4), in good 
agreement with the results from our MRM assay (Fig. 3).
Various studies have demonstrated that abnormal changes to sirtuin proteins occur during disease states as 
well as ageing. SIRT2 accumulates with age in the mouse brain and spinal cord22. Other recent studies have shown 
that SIRT1 decreases with age in the rat brain31 and SIRT2 is upregulated in brain tumours32. Hence, there is 
great value in developing robust quantitative assays such as MRM mass spectrometry to accurately quantify these 
proteins in control vs disease states. Another important aspect of sirtuin biology is that their deacetylase activity 
is nicotinamide and NAD+ dependent, establishing a direct link between their function and energy metabolism. 
To improve sensitivity, we found our fractionation method of running the samples on SDS PAGE and excising 
gel bands corresponding to the molecular weights of the intact sirtuin proteins to improve detection sensitivity. 
Figure 4. SIRT1-3 protein expression in animal organs. SIRT1-3 protein expression in guinea pig (Panel A) 
and mouse organs (Panel B). SIRT2 was found to be the most abundant sirtuin in guinea pig, with higher levels 
expressed in the brain (*p < 0.01, n = 2) compared to liver and kidney. SIRT2 in mouse was not quantified due 
to peptide sequence difference with the human peptide standards.
www.nature.com/scientificreports/
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The use of more sensitive mass spectrometers with high resolution MRM capability may improve detection of 
low abundant sirtuins and/or allow removal of the gel fractionation step. This would allow for sample lysates to 
be digested and analysed directly and decrease sample processing time. Using hybrid mass spectrometers capable 
Figure 5. Sirtuin expression in human brain cells and tissue using immunohistochemical staining of astrocytes 
(Panel A row 1–4) and human frontal lobe brain tissue (Panel A, row 5), PCR of SIRT1 and SIRT2 mRNA in 
occipital, frontal and hippocampal human control brain (Panel B) and cropped images of western blotting of 
SIRT1-3 protein expression in human control frontal lobe brain tissue (n = 3) at molecular weights of approx 
40 kDa, 50 kDa and 30 kDa respectively (Panel C). Full length blots are presented in Supplementary Figure S4.
www.nature.com/scientificreports/
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of high resolution and accurate mass measurements such as the quadrupole-orbitrap may overcome these issues 
and yield better sensitivity for high-complexity samples. This will help future validation of levels in large cohorts 
which may be useful for the identification of sirtuins as potential biomarkers.
Collectively, our results add further insights to the limited data which currently exist regarding the expression 
of sirtuins in the human CNS. This technique provides a powerful tool and helps improve upon the limitations 
of current protocols. While mass spectrometry based assays for protein quantification may still have some bar-
riers to overcome before they can be used in a clinical setting due to low throughput and expense compared to 
methods such as ELISA, they have great value in investigating lower abundance proteins such as sirtuins in com-
plex samples such as the brain with great sensitivity and specificity. Furthermore the current approach could be 
extended to develop isotope specific sirtuin assays, or extended to other species by use of appropriate synthetic 
peptide standards. MRM mass spectrometry can also be utilised for the quantification of sirtuin related metabo-
lites and thus targeted mass spectrometry methodologies have the potential to not only validate and complement 
currently established methods for investigation of sirtuin protein expression changes but can also help build a 
larger view of sirtuin biology in the normal brain and in disease conditions by linking sirtuin protein expression 
with metabolism.
Methods
Selection of target sirtuin peptides. Recombinant protein standards were purchased for seven human 
sirtuins (Cayman Chemical, USA), and 5 μ g of each was run by 1D SDS-PAGE gel and colloidal coomassie 
stained. Sirtuin bands were excised, trypsin digested overnight followed by LC-MS/MS analysis on a QToF Ultima 
API hybrid tandem mass spectrometer (Micromass, UK) as previously described33–35 and a detailed method is 
provided in Supplementary Protocols. The two peptides with the highest signal intensity for each sirtuin were 
cross-referenced with Skyline software (MacCoss Lab Software, USA). Peptide sequences were checked to ensure 
no overlap with other sirtuins. Sirtuin standards were run using MRM LC-MS/MS on a 4000 Q TRAQ (SCIEX, 
USA) mass spectrometer to ensure good signals were detected for all 14 peptides selected for the final list (two 
unique peptides for each sirtuin). See Supplementary Tables S2 and S4 and supplementary protocols for peptide 
sequences and light and heavy product ions for all 14 peptides. The full list of transitions and corresponding col-
lision energies and MRM method details are provided in Supplementary Table S5.
Targeted mass spectrometry. MRM analyses were performed on a 4000 Q TRAP hybrid triple quadru-
pole linear ion trap mass spectrometer (SCIEX, USA) interfaced with a nanospray ion source, operating in posi-
tive ion mode and controlled by Analyst 1.5 software. Peptides were concentrated and desalted onto a micro C18 
precolumn (500 μ m × 2 mm, Michrom Bioresources, USA) with H2O:CH3CN (98:2, 0.05% TFA) at 15 μ l/min. 
After a 4 min wash, the pre-column was automatically switched (10 port valve, Valco, USA) into line with a nano 
column (as described in the previous section). Peptides were eluted using a linear gradient of H2O:CH3CN (98:2, 
0.1% formic acid) to H2O:CH3CN (36:64, 0.1% formic acid) at ~300 nl/min over 30 minutes. Samples were ana-
lyzed with an ion spray voltage of 2.4 kV, curtain gas flow of 12 and nebulizing gas flow of 5 L/min. Quadrupoles 
were operated in the low resolution mode, and the dwell time was 50 ms. For validation runs, the MRM experi-
ment triggered MS/MS spectrum acquisition. MS/MS spectra were acquired in the trap mode (enhanced product 
ion) with dynamic fill time, Q1 was operated using low resolution. Each sirtuin protein (SIRT1-7, 2 peptides per 
protein) were run with 12 transition ions per run, per protein and with a 50 ms dwell time. See Supplementary 
Table S5 for a full list of transitions for each peptide and corresponding collision energies (estimated using Skyline 
software).
Sirtuin Peptide Standards. Multiple point calibration was used where a series of standard ‘light’ peptides 
with known concentrations together with fixed amounts of stable isotope-labelled ‘heavy’ peptides (100 fmol/μ l) 
were used to generate calibration curves (Fig. 1). The curves were expressed as ratios of light/heavy peak area 
(y-axis) versus concentration of light peptide (x-axis) for each of the 14 peptides selected. A commercially avail-
able stable isotope-labelled peptide standard (AQUA peptide, Sigma, USA) was used for absolute quantification 
of proteins. This heavy surrogate of each of the peptide standards is added at a constant level to all samples and 
standards and is used for correction of sample losses during workup and normalisation across runs, allowing 
accurate quantification of the target protein in samples. Peptides labelled with a stable isotope (13C and 15N) are 
chemically identical to their native counterparts and have identical chromatographic behaviour but can be distin-
guished from the calibration standards based on a small specific mass difference.
Preparation of Cell Cultures, Tissues, CSF and Plasma. Cells. Adult human primary micro-
glia, astrocytes, neurons and oligodendrocytes were cultured from resected normal adult brain tissue follow-
ing removal of brain tumour with informed consent at the Minimally Invasive Cancer Centre, Prince of Wales 
Hospital, Sydney, Australia. Astrocytes were prepared from the mixed brain cell cultures using a protocol previ-
ously described by Guillemin et al.36. Cell culture procedures are described in detail in Supplementary Protocols. 
All cells and cell lines were lysed using RIPA buffer followed by probe sonication and cell debris removed by 
centrifugation at 10,000RPM for 5 min. Total protein concentration was assayed in the supernatant using the 
Pierce BCA protein assay kit (Life Technologies, Australia), and three 10 μ g replicates were run by 1D SDS-PAGE 
followed by colloidal coomassie staining.
Human Tissues. 20 μ g of protein from five individual control post mortem brain tissue samples were extracted 
as described for cells in the previous section, and run on a 1D SDS-PAGE gel and coomassie stained. Detailed 
patient information including age, sex and post-mortem tissue collection times can be found in Supplementary 
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Table S6. For the fractionated samples, 200 mg of frontal lobe brain tissue from five control subjects were pooled 
and differential detergent fractionation performed to obtain cytosol, nucleus, cytoskeletal and membrane protein 
fractions37. Each fraction (20 μ g) was run on a 1D SDS-PAGE gel and coomassie stained.
Animals. Female guinea pigs (Dunkin–Hartley) and C57BL6 mice were housed in temperature-controlled 
rooms (21–22 °C; 49–55% humidity) with 12 h light-dark cycle (lights on 7:00–19:00). Food and water was avail-
able ad libitum. Wild type mice and guinea pig organs were lysed (RIPA buffer) by probe sonication. Proteins 
(20 μ g/lane) were run by 1D SDS-PAGE and coomassie stained. Protein concentrations were determined using 
the Pierce BCA protein assay kit (Life Technologies, Australia).
CSF and plasma. CSF samples were collected by standard lumbar puncture from five patients assessed as clin-
ically well after investigation for suspected meningitis (Supplementary Figure S5), returning normal results for 
routine CSF pathology markers (white cell count, protein, glucose and bacterial sterility). Aliquots (50 μ l) from 
each patient were obtained for our study. Control human plasma from a healthy individual was immunodepleted 
of the six most abundant plasma proteins using an Hu6 column (Agilent, USA) according to manufacturer’s 
instructions38. For immunodepletion using the Multiple Affinity Removal System Hu6 column and buffer kit 
(Agilent, Santa Clara, CA, USA). 24 μ l EDTA plasma was diluted into 120 μ l Buffer A. 100 μ l of this diluted EDTA 
plasma was injected onto the Hu6 column connected to a HP 1090 HPLC system (Agilent, Santa Clara, CA, USA) 
and the low abundance protein fraction was collected following manufacturer’s instructions. The low abundance 
protein fractions from six injections were pooled, buffer exchanged and concentrated into 45 mM NaHCO3 using 
Amicon 3 kDa centrifugal devices (Millipore, Billerica, MA, USA). CSF protein (5 μ g) and depleted plasma pro-
tein (20 μ g) as determined by a BCA protein assay were run on a 1D SDS-PAGE gel and colloidal coomassie 
stained.
For all samples, the band corresponding to the molecular weight for each sirtuin was excised (see 
Supplementary Figure S6), de-stained and trypsin digested overnight with heavy sirtuin peptides added as 
internal standards to all samples prior to digestion (the internal standard was added at a constant level to all 
samples and standards, and was at about the midrange of the standard curve). The tryptic peptides were dried 
under vacuum (Savant Speedvac, Thermo Scientific, USA), reconstituted in 0.1% formic acid (5 μ l), injected into 
the mass spectrometer (1 μ L) and analysed using MRM. Peak area ratios (light/heavy) were calculated for each 
endogenous peptide (light) relative to the spiked isotope-labelled (heavy) peptide using Skyline MRM analysis 
software. Protein concentrations were determined using calibration curves. All samples were fractionated by 
1D-SDS-PAGE to reduce sample complexity. A workflow of the sample preparation procedure can be found in 
Supplementary Figure S3.
To test for matrix effects relevant to the in-gel processed sirtuins, Hu6 depleted plasma was run by SDS-PAGE 
(see Supplementary Figure S7) and sirtuin peptide standard curves prepared by spiking with excised gel bits taken 
from the expected migration position of the intact sirtuin. Additional matrices tested included buffer only (0.1% 
formic acid, no gel bit), a blank gel bit, and the spiked standard curves are shown in Supplementary Figure S2.
To determine recoveries of sirtuin proteins, commercial intact sirtuin standards were run by SDS PAGE (5 μ g 
per lane). Hu6 high abundance depleted plasma spiked with 2 ug and 5 μ g of the sirtuin standard for SIRT1, 2, 3, 
5 and 6 were also run on the same gel (Supplementary Figure S8). Sirtuin 5 μ g spike recoveries were calculated in 
the LAP spike relative to the sirtuin 5 μ g standard protein in buffer only samples. The sirtuin 2 μ g spike recoveries 
were calculated in the LAP spike relative to values extrapolated from the results of the sirtuin 5 μ g standard pro-
tein in buffer only samples (Supplementary Table S1).
Sirtuin mRNA Expression in Human Brain Tissue using PCR. For the gene expression studies RNA 
was extracted from human brain cells using RNeasy mini kits (Qiagen, Germany). The cDNA was prepared 
using SuperScript III First-Strand Synthesis System and random hexamers (Invitrogen Corporation, USA) as 
previously described39. Detailed protocol and primer sequences are described in Supplementary Protocols and 
Supplementary Table S7 respectively.
Sirtuin Expression in Human Brain Cells and Tissue using immunohistochemical staining. 
Post mortem brain tissue from a male patient aged 63 years was obtained from the Sydney Brain Bank. 
Immunohistochemical staining was performed as previously published40 and was performed using anti-human 
sirtuin (1:250) primary antibodies (raised in rabbit). The full protocol description can be found in Supplementary 
Protocols.
Sirtuin Protein Expression in human control brain tissue using western blotting. Protein from 
three individual control post mortem frontal brain tissue samples were extracted as described in the previous 
section, and run on a 1D SDS-PAGE gel (20 μ g protein per lane), and western blotted with antibodies for SIRT1, 
SIRT2 and SIRT3 (details provided in Supplementary Protocols and list of antibodies used in Supplementary 
Table S8).
Statistics. Sirtuin concentrations are presented as means ± SEM using peak area ratios of light and heavy 
peptides obtained from Skyline MRM Proteomics software v3.1 (MacCoss Lab, USA). Sirtuins were quantified 
based on an average of data from both peptides used for each sirtuin where possible. Statistical comparisons were 
performed using two-tailed student t-tests assuming equal variance. Differences between groups were considered 
statistically significant at the p < 0.05 level.
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Ethics. All human and animal brain tissue samples were obtained and experiments conducted in accordance 
with the guidelines of the National Health and Medical Research Council of Australia and were approved by 
the University of New South Wales Human Research Ethics Committee (human brain tissue reference number 
HC12563) and the University of New South Wales Animal Care Ethics Committee (guinea pig tissue reference 
number 14/40B and mice 13/39B). Adult human primary microglia, astrocytes, neurons and oligodendrocytes 
were cultured from resected normal adult brain tissue following removal of brain tumour with informed consent 
at the Minimally Invasive Cancer Centre, Prince of Wales Hospital, Sydney, Australia (reference number X12-
0314 and HREC/12/RPAH/481). All control CSF samples were obtained with ethics approval from the Sydney 
Adventist Hospital, Sydney Australia, with informed consent obtained from all subjects (reference number 
SAHHREC #13-02).
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